hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06287554, orgStudyIdInfo id: 404/2024, briefTitle: Effect of Early Implementation of Prone Positioning, acronym: prone, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-03-04, primaryCompletionDateStruct date: 2022-04-20, completionDateStruct date: 2022-04-20, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Zulekha Hospitals, class: OTHER, collaborators name: Al-Azhar University, descriptionModule briefSummary: Background and objective: The ramifications of early lung protective measures and prone positioning on the ICU length of stay rates of participants admitted to the ICU with acute respiratory distress syndrome amid the COVID-19 pandemic constitute a pivotal examination. The study aims to identify the effect of early prone positioning on the length of stay, discharge rate, and number of tracheostomized patients in the ICU., conditionsModule conditions: Severe Acute Respiratory Syndrome, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: OTHER, enrollmentInfo count: 70, type: ACTUAL, armsInterventionsModule interventions name: PRONE POSITION, outcomesModule primaryOutcomes measure: Number of discharged patients, secondaryOutcomes measure: The total length of stay, secondaryOutcomes measure: ICU length of stay, secondaryOutcomes measure: Patients who underwent tracheostomy procedures, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Al-Azhar faculty of medicine, city: Cairo, zip: 12546, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06287541, orgStudyIdInfo id: 2023-SR-486, briefTitle: The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-07-01, primaryCompletionDateStruct date: 2025-12-01, completionDateStruct date: 2027-07-01, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital with Nanjing Medical University, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to evaluate the efficacy of using a urine biomarker test to guide the decision-making process regarding the necessity of reTURBT in NMIBC patients. The main question aims to answer whether patients with negative urine biomarker tests can safely avoid reTURBT without compromising recurrence-free survival. Participants who have completed the initial TURBT and tested negative for the urine biomarker will be enrolled in the study. They will then be randomized 1:2 into two groups:Group A: Participants will not receive reTURBT and Group B: Participants will undergo reTURBT. Researchers will compare the RFS rates between Group A (no reTURBT) and Group B (reTURBT) to determine if the urine biomarker test can safely spare patients from unnecessary reTURBT., conditionsModule conditions: Non Muscle Invasive Bladder Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Participants who meet the inclusion criteria are randomized 1:2 into two parallel groups. Group A: Participants assigned to this group will not undergo reTURBT. They will receive standard follow-up care as per institutional guidelines.Group B: Participants assigned to this group will undergo reTURBT as part of their treatment protocol. Following reTURBT, they will also receive standard follow-up care. Outcome measures of recurrence rate and RFS would be compared between the two groups to determine the effectiveness and safety of the urine genetic test-guided approach compared to standard care with reTURBT.Throughout the study period, both groups are followed up simultaneously, allowing for parallel comparisons of outcomes., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 428, type: ESTIMATED, armsInterventionsModule interventions name: Urine biomarker -Guided without reTURBT, outcomesModule primaryOutcomes measure: 2-year RFS rate, secondaryOutcomes measure: RFS, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of Nanjing Medical University, status: RECRUITING, city: Nanjing, state: Jiangsu, zip: 210029, country: China, contacts name: Qiang Lv, Ph.D, role: CONTACT, email: doctorlvqiang@sina.com, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False
protocolSection identificationModule nctId: NCT06287515, orgStudyIdInfo id: 2023-0940, secondaryIdInfos id: NCI-2024-01986, type: OTHER, domain: NCI-CTRP Clinical Registry, briefTitle: Hypophysectomy by Stereotactic Radiosurgery for Cancer-Related Pain, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08-31, primaryCompletionDateStruct date: 2025-07-01, completionDateStruct date: 2027-07-01, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: M.D. Anderson Cancer Center, class: OTHER, descriptionModule briefSummary: To learn if hypophysectomy (treatment of the pituitary gland) using a type of radiation treatment called stereotactic radiosurgery (SRS) can help to relieve cancer-related pain., conditionsModule conditions: Hypophysectomy, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Stereotactic Radiosurgery, outcomesModule primaryOutcomes measure: Safety and adverse events (AEs), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: MD Anderson Cancer Center, city: Houston, state: Texas, zip: 77030, country: United States, contacts name: Chenyang Wang, MD, role: CONTACT, phone: 832-710-1570, email: cwang23@mdanderson.org, contacts name: Chenyang Wang, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 29.76328, lon: -95.36327, hasResults: False
protocolSection identificationModule nctId: NCT06287502, orgStudyIdInfo id: KHRehab_LeungHC_2, briefTitle: Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2022-09-09, primaryCompletionDateStruct date: 2024-04-30, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Kowloon Hospital, Hong Kong, class: OTHER, descriptionModule briefSummary: This is a prospective parallel group, double-blinded randomized controlled trial. Subjects are randomized into two groups - the intervention group and waitlist control group. Subjects received resistance, aerobic, flexibility and balance exercise training; and nutritional supplement containing β-hydroxy β-methylbutyrate (HMB). The intervention group would first receive the intervention during the 12-week study period. Meanwhile, the waitlist control group would receive 12 weeks of conventional care. After the study period, they would receive the same intervention., conditionsModule conditions: Sarcopenia, conditions: Osteoporosis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: β-hydroxy β-methylbutyrate (HMB), interventions name: Resistance, aerobic, flexibility and balance exercise training, outcomesModule primaryOutcomes measure: Grip strength, secondaryOutcomes measure: Body weight, secondaryOutcomes measure: Body mass index, secondaryOutcomes measure: Appendicular skeletal muscle mass index, secondaryOutcomes measure: 6-metre walk test, secondaryOutcomes measure: 5-time chair stand test, secondaryOutcomes measure: Short Physical Performance Battery (SPPB), eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Kowloon Hospital, city: Kowloon, country: Hong Kong, geoPoint lat: 22.31667, lon: 114.18333, hasResults: False
protocolSection identificationModule nctId: NCT06287489, orgStudyIdInfo id: No.:2023-08-010ACF, briefTitle: Effects of Mediterranean Diet on Subjective Cognitive Decline, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-26, primaryCompletionDateStruct date: 2025-10-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Chih-Ping Chung, class: OTHER_GOV, collaborators name: National Yang Ming Chiao Tung University, descriptionModule briefSummary: Research Questions:1. Due to the fact that most participants in past clinical trials on the Mediterranean diet were cognitively healthy individuals, and while the observed effects were significant, they were not particularly substantial, does the Mediterranean diet have similarly significant and more pronounced effects on both physical and cognitive functions in older adults with subjective cognitive decline (SCD)?2. What is the mechanism behind the effects of the Mediterranean diet on physical or/and cognitive function? Is it through vascular protection or improvements in brain structure/brain network function?Research Objective:Conduct a cross-over randomized controlled trial to investigate the effects of a three-month Mediterranean diet on the physical and cognitive functions of older adults with subjective cognitive decline (SCD) in the community. Utilize brain MRI and circulatory biomarkers measurements to elucidate the underlying mechanisms., conditionsModule conditions: Subjective Cognitive Decline, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: Mediterranean diet phase X regular diet phase, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Mediterranean diet, interventions name: Regular diet, outcomesModule primaryOutcomes measure: Cognitive functional change, primaryOutcomes measure: Physical function 1 - gait speed change, primaryOutcomes measure: Physical function 2 - handgrip strength change, primaryOutcomes measure: Physical function 3 - stand from chair speed change, primaryOutcomes measure: Brain MRI structural change - total and regional voxel-based brain parenchymal features change, primaryOutcomes measure: Brain MRI functional change - total and regional voxel-based brain functional features change, primaryOutcomes measure: Brain MRI neurovascular lesion change - small vessel disease markers, primaryOutcomes measure: Brain MRI neurovascular structural change - microvascular density, secondaryOutcomes measure: AD circulatory biomarkers, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Taipei Veterans General Hospital, status: RECRUITING, city: Taipei, zip: 11217, country: Taiwan, contacts name: Chih-Ping Chung, MD PhD, role: CONTACT, phone: +886-2-918155976, email: pin324pin324@gmail.com, geoPoint lat: 25.04776, lon: 121.53185, hasResults: False
protocolSection identificationModule nctId: NCT06287463, orgStudyIdInfo id: DCC-3084-01-001, briefTitle: Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2026-08, completionDateStruct date: 2027-08, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Deciphera Pharmaceuticals LLC, class: INDUSTRY, descriptionModule briefSummary: This is a multicenter, Phase 1/2 clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with solid tumors. Additional modules exploring other cancers may be added to the master protocol at a later date. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion)., conditionsModule conditions: Advanced Solid Tumor, conditions: RAF Mutation, conditions: RAS Mutation, conditions: NF1 Mutation, conditions: Non-Small Cell Lung Cancer, conditions: Pancreatic Ductal Adenocarcinoma, conditions: Melanoma, conditions: BRAF Gene Mutation, conditions: CRAF Gene Mutation, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 140, type: ESTIMATED, armsInterventionsModule interventions name: DCC-3084, outcomesModule primaryOutcomes measure: Number of Participants with Dose-limiting Toxicities (DLTs) (ModA Part 1), primaryOutcomes measure: Objective Response Rate (ORR) (ModA Part 2), secondaryOutcomes measure: ORR (ModA Part 1), secondaryOutcomes measure: Progression-Free Survival (PFS) (ModA Part 1 and 2), secondaryOutcomes measure: Overall Survival (OS) (ModA Part 1 and 2), secondaryOutcomes measure: Pharmacokinetics (PK): Maximum observed plasma drug concentration (Cmax) (ModA Part 1 and 2), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: NEXT Oncology, city: San Antonio, state: Texas, zip: 78229, country: United States, contacts name: Ildefonso Ismael Rodriguez Rivera, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 29.42412, lon: -98.49363, locations facility: NEXT Oncology Virginia, city: Fairfax, state: Virginia, zip: 22031, country: United States, contacts name: Alexander Spira, MD, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 38.84622, lon: -77.30637, hasResults: False
protocolSection identificationModule nctId: NCT06287437, orgStudyIdInfo id: B2023-335R, briefTitle: HRS9531 Controls Weight Regain in Obese Subjects, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2025-06-30, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Shanghai Zhongshan Hospital, class: OTHER, descriptionModule briefSummary: This is a single-center, double-blinded, randomized, placebo-controlled phase II study to explore the effectiveness, safety and energy balance mechanism of low-frequency continuous subcutaneous injection of HRS9531 to inhibit weight regain in obese non-diabetic and obese diabetic patients, conditionsModule conditions: Obesity, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 72, type: ESTIMATED, armsInterventionsModule interventions name: HRS9531, interventions name: HRS9531 placebo, outcomesModule primaryOutcomes measure: Percent Change in Body Weight from 24 weeks, secondaryOutcomes measure: Energy intake change from 24 weeks, secondaryOutcomes measure: Energy expenditure change from 24 weeks, secondaryOutcomes measure: Metabolic adaptation from 24 weeks, secondaryOutcomes measure: Systolic blood pressure and diastolic blood pressure change from 24 weeks, secondaryOutcomes measure: Body fat rate change from 24 weeks, secondaryOutcomes measure: Serum total cholesterol change from 24 weeks, secondaryOutcomes measure: Triglyceride change from 24 weeks, secondaryOutcomes measure: Nonestesterified fatty acid change from 24 weeks, secondaryOutcomes measure: Energy intake at baseline, secondaryOutcomes measure: Energy expenditure at baseline, secondaryOutcomes measure: Appetite at baseline (assessed by Visual Analogue Scale subjective rating scale), secondaryOutcomes measure: Percent Change in Body Weight at 24 weeks, secondaryOutcomes measure: Appetite at 24 weeks (assessed by Visual Analogue Scale subjective rating scale), secondaryOutcomes measure: Energy expenditure at 24 weeks, secondaryOutcomes measure: Energy intake at 24 weeks, otherOutcomes measure: Change of body weight at 24 weeksl from baseline, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Xiaoying Li, city: Shanghai, country: China, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06287424, orgStudyIdInfo id: HMO-2O-0536, briefTitle: The Efficacy Of AGE On Periodontitis, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-04-04, primaryCompletionDateStruct date: 2022-09-30, completionDateStruct date: 2023-01-01, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Hadassah Medical Organization, class: OTHER, collaborators name: Wakunaga Pharmaceutical Co., Ltd., descriptionModule briefSummary: The objective of this study is to assess the long-term efficacy of "AGE among on deep periodontal pockets by different doses of "AGE" for a period of 18 months., conditionsModule conditions: Periodontitis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: 4 Regimen parralel groups, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, maskingDescription: Eligible subjects will be stratified based on Screening mean PPD (above or below 2mm), mean GBI (above or below 0.44), mean age (above or below 45 years old), gender (male or female) and tobacco use (yes or no). Within strata, subjects will be randomly assigned to one of the treatment groups using an encoded program. This assignment process and the distribution of test products will be conducted in a protected area that will ensure blinding of the examiner to the identity of the test products., whoMasked: PARTICIPANT, enrollmentInfo count: 300, type: ACTUAL, armsInterventionsModule interventions name: Aged Garlic Extract, interventions name: Placebo, outcomesModule primaryOutcomes measure: Gingival Bleeding Index (GBI), primaryOutcomes measure: Probing Pocket Depth (PPD), eligibilityModule sex: ALL, minimumAge: 30 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Hebrew University, city: Jerusalem, zip: 9112102, country: Israel, geoPoint lat: 31.76904, lon: 35.21633, hasResults: False
protocolSection identificationModule nctId: NCT06287411, orgStudyIdInfo id: 202436, briefTitle: Role of FAPI PET/MR Combined With Gadoxetate Disodium in Assessing Hepatic Malignancies, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Xiao Chen, class: OTHER, descriptionModule briefSummary: This study aimed to prospectively evaluate the utility of fibroblast activation protein inhibitor (FAPI) positron emission tomography (PET)/magnetic resonance (MR) combined with gadoxetate disodium in patients with clinical suspected hepatic malignancies (lesion diameter ≤ 3.0cm), with histopathological findings obtained from biopsy or resected surgical specimens, or follow-up results as reference standards., conditionsModule conditions: Hepatic Malignancies, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: FAPI PET/MR combined with gadoxetate disodium, outcomesModule primaryOutcomes measure: Diagnostic performance, secondaryOutcomes measure: Quantitative parameters of PET/MR, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Nuclear Medicine, Daping Hospital of Army Medical University, status: RECRUITING, city: Chongqing, state: Chongqing, zip: 400010, country: China, contacts name: Xiao Chen, Ph.D, role: CONTACT, phone: 15922970174, email: xiaochen229@foxmail.com, geoPoint lat: 29.56278, lon: 106.55278, hasResults: False
protocolSection identificationModule nctId: NCT06287385, orgStudyIdInfo id: NELN202212A, briefTitle: An Exploratory RWE Study Exploring Effects of a Goat Milk Based Young Child Formula on Health Benefits, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-15, primaryCompletionDateStruct date: 2025-05-15, completionDateStruct date: 2025-12-15, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Danone Nutricia, class: INDUSTRY, descriptionModule briefSummary: This is an exploratory real-world study designed to gain insight into the role of the product in terms of health benefits in toddlers, with the potential to generate hypotheses on key and other exploratory objectives., conditionsModule conditions: Healthy Children, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: Goat-milk Based Formula, outcomesModule primaryOutcomes measure: Stool characteristics, secondaryOutcomes measure: Gastrointestinal symptoms, secondaryOutcomes measure: Quality of life of subjects, secondaryOutcomes measure: Lifestyle-related immune indicators, otherOutcomes measure: Safety parameters, eligibilityModule sex: ALL, minimumAge: 1 Year, maximumAge: 2 Years, stdAges: CHILD, contactsLocationsModule locations facility: Peking University Third Hospital, city: Beijing, state: Beijing, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False